Published

Capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC

Summary by urologytime.com
Data from the CAPItello-281 trial also showed a trend toward an improvement in overall survival.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)